# US 2023/0414678 A1 · Shelf- stable ammonia oxidizing microorganism preparations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414678 A1
- Document ID: US20230414678A1
- Status: Published application
- Kind: A1
- Application number: 18/367,445
- Filed: 2023-09-12
- Published: 2023-12-28
- Earliest claimed: 2020-05-21
- Assignees: Aobiome LLC
- Applicants: Aobiome LLC
- Inventors: Carson Alexis Goddard
- Web page: https://patentgrep.com/patent/US20230414678A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- C12N 1/066: by physical processes
- A61K 8/99: from microorganisms other than algae or fungi, e.g. protozoa or bacteria
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61Q 19/00: Preparations for care of the skin
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 2800/10: General cosmetic use
- A61K 2800/87: Application Devices; Containers; Packaging
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Methods of distributing a preparation including providing the preparation comprising ammonia oxidizing microorganisms (AOM), wherein, during distribution, the preparation is exposed to a temperature greater than about 4° C. are disclosed. Methods of treating a subject comprising administering the preparation wherein less than 70% of the AOM are viable are also disclosed. Methods of treating a subject comprising administering the preparation at room temperature are also disclosed. Methods of treating Autosomal dominant hyper-IgE syndrome (AD-HIES) with preparations comprising AOM are disclosed. Methods of treating immunodysregulation polyendocrinopathy enteropathy-X-linked (IPEX) with preparations comprising AOM are disclosed. Methods of producing shelf-stable products from the preparation are also disclosed. Shelf-stable preparations of AOM are also disclosed.

## Claims

### Claim 1

A method of distributing a preparation, comprising:
providing a preparation comprising live ammonia oxidizing microorganisms (AOM),
wherein, during distribution, the preparation is exposed to an environment having a temperature greater than about 4° C.,
thereby distributing the preparation.

### Claim 2

A method of treating a subject, comprising:
administering to the subject a therapeutically effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM),
wherein less than about 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.5%, or 0.1% of the ammonia oxidizing microorganisms are viable.

### Claim 3

A method of treating a subject, comprising:
administering to the subject a therapeutically effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM),
wherein the preparation is at a temperature greater than or about room temperature e.g., between about 20° C.-25° C., when administered.

### Claim 4

A method of treating Autosomal dominant hyper-IgE syndrome (AD-HIES) in a subject, comprising:
administering to the subject a therapeutically effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM),
thereby treating the Autosomal dominant hyper-IgE syndrome (AD-HIES).

### Claim 5

A method of treating immunodysregulation polyendocrinopathy enteropathy-X-linked (IPEX) in a subject, comprising:
administering to the subject a therapeutically effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM),
thereby treating the immunodysregulation polyendocrinopathy enteropathy-X-linked (IPEX).

### Claim 6

A method of producing a shelf-stable cosmetic, therapeutic, or consumer product, comprising:
formulating a preparation comprising ammonia oxidizing microorganisms (AOM) into a powder, cream, ointment, or lotion; and
packaging the preparation into the cosmetic, therapeutic, or consumer product,
wherein less than about 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.5%, or 0.1% of the ammonia oxidizing microorganisms in the cosmetic or therapeutic product are viable.

### Claim 7

The method of any of the preceding claims, comprising providing the preparation comprising live ammonia oxidizing microorganisms.

### Claim 8

The method of any of the preceding claims, wherein less than about 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.5%, or 0.1% of the ammonia oxidizing microorganisms are viable.

### Claim 9

The method of any of the preceding claims, wherein, the preparation is exposed to an environment having a temperature greater than about 4° C.

### Claim 10

The method of any of the preceding claims, wherein the preparation is packaged into a container.

### Claim 11

The method of any of the preceding claims, wherein the preparation is packaged into a plurality of containers, e.g., at least 2, 3, 6, 8, 10, or 20 containers.

### Claim 12

The method of any of the preceding claims, wherein the preparation is packaged into an end use container.

### Claim 13

The method of any of the preceding claims, wherein the preparation is packaged into a plurality of separate end use containers, e.g., at least 2, 4, 6, 8, 10, 20, 50, or 100 end use containers.

### Claim 14

The method of any of the preceding claims, comprising supplying (or causing a designee to supply) the preparation or packaged end use container to a recipient.

### Claim 15

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container is exposed to an environment having a temperature greater than about 10° C.

### Claim 16

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container is exposed to an environment having a room temperature, e.g., between about 20° C.-25° C.

### Claim 17

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container attains a temperature greater than about 4° C.

### Claim 18

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container attains a temperature greater than about 10° C.

### Claim 19

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container attains a temperature greater than about room temperature, e.g., between about 20° C.-25° C.

### Claim 20

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container is exposed to the environment for a period of time of at least about 1 hour, 6 hours, 12 hours, 18 hours, 1 day, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or 5 years.

### Claim 21

The method of any of the preceding claims, wherein the environment is a storage environment.

### Claim 22

The method of any of the preceding claims, wherein the environment is a shipping environment, e.g., a mail or a commercial delivery shipping environment.

### Claim 23

The method of any of the preceding claims, wherein the environment is a shipping environment, e.g., a cargo or a freight transport shipping environment.

### Claim 24

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container attains a temperature greater than about 4° C. for at least about 1 hour, 6 hours, 12 hours, 18 hours, 1 day, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or 5 years.

### Claim 25

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container attains a temperature greater than about 10° C. for at least about 1 hour, 6 hours, 12 hours, 18 hours, 1 day, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or 5 years.

### Claim 26

The method of any of the preceding claims, wherein, during distribution, the preparation or packaged end use container attains a temperature greater than about room temperature, e.g., between about 20° C.-25° C., for at least about 1 hour, 6 hours, 12 hours, 18 hours, 1 day, 3 days, days, 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or 5 years.

### Claim 27

The method of any of the preceding claims, wherein supplying (or causing the designee to supply) the preparation or packaged end use container to the recipient comprises making the preparation or packaged end use container available on an internet-based outlet.

### Claim 28

The method of any of the preceding claims, wherein supplying (or causing the designee to supply) the preparation or packaged end use container to the recipient comprises making the preparation or packaged end use container available at a non-internet-based outlet, e.g., a store.

### Claim 29

The method of any of the preceding claims, wherein, upon packaging, e.g., into an end use container, at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%, or 99.9% of the ammonia oxidizing microorganisms are viable.

### Claim 30

The method of any of the preceding claims, wherein, upon packaging, e.g., into an end use container, at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%, or 99.9% of the ammonia oxidizing microorganisms are active.

### Claim 31

The method of any of the preceding claims, wherein, after distribution, less than about 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.5%, or 0.1% of the ammonia oxidizing microorganisms are viable.

### Claim 32

The method of any of the preceding claims, wherein, after distribution, at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%, or 99.9% of the ammonia oxidizing microorganisms are inactive.

### Claim 33

The method of any of the preceding claims, wherein, upon packaging, e.g., into an end use container, less than about 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.5%, or 0.1% of the ammonia oxidizing microorganisms are viable.

### Claim 34

The method of any of the preceding claims, wherein, upon packaging, e.g., into an end use container, less than about 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.5%, or 0.1% of the ammonia oxidizing microorganisms are inactive.

### Claim 35

The method of any of the preceding claims, wherein at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%, 99.9%, or substantially all of the ammonia oxidizing microorganisms are heat killed, e.g., prior to packaging.

### Claim 36

The method of any of the preceding claims, wherein the container, e.g., end use container, comprises a polymer bottle, e.g., a spray, aerosol, or mist bottle.

### Claim 37

The method of any of the preceding claims, wherein the container, e.g., end use container, comprises a squeezable container, e.g., squeeze bottle or tube.

### Claim 38

The method of any of the preceding claims, wherein the container, e.g., end use container, is substantially free of a vacuum bag.

### Claim 39

The method of any of the preceding claims, wherein the container, e.g., end use container, is not configured to inhibit or reduce retrograde flow.

### Claim 40

The method of any of the preceding claims, wherein the container, e.g., end use container comprises polymer, e.g., polyethylene terephthalate (PET), high density polyethylene (HDPE), polypropylene, polycarbonate, polytetrafluoroethylene (Teflon®), polyviylidene fluoride (PVDF), or a cellulosic, glass, aluminum, or cardboard.

### Claim 41

The method of any of the preceding claims, wherein the container, e.g., end use container, is configured to allow passage of oxygen.

### Claim 42

The method of any of the preceding claims, wherein the container, e.g., end use container, is configured to allow passage of at least about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99, or 100 percent of transmission of ionizing radiation, e.g., with gamma rays, e.g., with x-rays, e.g., from an isotope, e.g., cobalt 60, or with ultraviolet, e.g., ultraviolet C (UVC) through the container.

### Claim 43

The method of any of the preceding claims, comprising treating a disease or disorder modulated by an activated immune cell in a subject.

### Claim 44

The method of any of the preceding claims, wherein the activated immune cell is a T helper cell or a regulatory T cell.

### Claim 45

The method of any of the preceding claims, wherein the activated immune cell is T helper type 1 (Th1), T helper type 2 (Th2), T helper type 17 (Th17), or regulatory T cell (Treg).

### Claim 46

The method of any of any of the preceding claims, wherein at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%, or 99.9% of the ammonia oxidizing microorganisms are inactive.

### Claim 47

The method of any of the preceding claims, wherein administration provides for upregulation, activation, downregulation, or suppression of a cytokine associated with an activated immune cell, e.g., IL-5, IL-13, IL-4, IFNγ, IL-12, IL-2, IL-18, IL-17, IL-21, IL-22, IL-10, and TFG-β

### Claim 48

The method of any of the preceding claims, wherein the preparation is at a temperature greater than about 4° C., when administered.

### Claim 49

The method of any of the preceding claims, wherein the preparation is at a temperature greater than about 10° C., when administered.

### Claim 50

The method of any of the preceding claims, wherein the preparation is at a temperature greater than about room temperature e.g., between about 20° C.-25° C., when administered.

### Claim 51

The method of any of the preceding claims, wherein a period of time of at least about 1 day, 3 days, 5 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or 5 years has elapsed between packaging and administration.

### Claim 52

The method of any of the preceding claims, wherein the subject is identified as having a disease or disorder modulated by an activated immune cell.

### Claim 53

The method of any of the preceding claims, wherein treatment comprises providing a therapeutic effect for a disease or disorder modulated by an activated immune cell.

### Claim 54

The method of any of the preceding claims, wherein the subject is identified as having a T helper type 1 (Th1) cell mediated disease.

### Claim 55

The method of any of the preceding claims, wherein the Th1 mediated disease is Celiac disease, multiple sclerosis, or diabetes, e.g., type 1 diabetes.

### Claim 56

The method of any of the preceding claims, wherein treatment comprises providing a therapeutic effect for a Th1 mediated disease or a symptom thereof.

### Claim 57

The method of any of the preceding claims, wherein the subject is identified as having a T helper type 2 (Th2) cell mediated disease or disorder.

### Claim 58

The method of any of the preceding claims, wherein the Th2 mediated disease or disorder is associated with atopic dermatitis, allergic rhinitis, asthma, or itch.

### Claim 59

The method of any of the preceding claims, wherein treatment comprises providing a therapeutic effect for a Th2 mediated disease or a symptom thereof.

### Claim 60

The method of any of the preceding claims, wherein the subject is identified as having a T helper type 17 (Th17) cell mediated disease or disorder.

### Claim 61

The method of any of the preceding claims, wherein the Th17 mediated disease or disorder is Autosomal dominant hyper-IgE syndrome (AD-HIES), rheumatoid arthritis, or irritable bowel syndrome.

### Claim 62

The method of any of the preceding claims, wherein treatment comprises providing a therapeutic effect for a Th17 mediated disease or a symptom thereof.

### Claim 63

The method of any of the preceding claims, wherein the subject is identified as having a regulatory T cell (Treg) cell mediated disease or disorder.

### Claim 64

The method of any of the preceding claims, wherein the Treg mediated disease or disorder is immunodysregulation polyendocrinopathy enteropathy-X-linked (IPEX).

### Claim 65

The method of any of the preceding claims, wherein treatment comprises providing a therapeutic effect for a Treg mediated disease or a symptom thereof.

### Claim 66

The method of any of the preceding claims, wherein the preparation is formulated as a spray, aerosol, or mist.

### Claim 67

The method of any of the preceding claims, wherein the preparation is formulated as a powder, cream, ointment, or lotion.

### Claim 68

The method of any of the preceding claims, wherein the preparation comprises a thickener and/or emulsifier.

### Claim 69

The method of any of the preceding claims, wherein the preparation has a viscosity of at least about 1 mPa·s, 10 mPa·s, 100 mPa·s, 1 Pa·s, 5 Pa·s, 10 Pa·s, or 20 Pa·s at room temperature, e.g., between about 20° C.-25° C.

### Claim 70

The method of any of the preceding claims, wherein the preparation comprises a talcum powder or cornstarch.

### Claim 71

The method of any of the preceding claims, wherein the preparation comprises a component that is toxic to AOM, e.g., an antimicrobial or a preservative, e.g., a preservative listed in Annex VI.

### Claim 72

The method of any of the preceding claims, further comprising combining the preparation with at least one preservative listed in Annex VI.

### Claim 73

The method of any of the preceding claims, comprising combining the preparation with at least 500 ppb of at least one preservative listed in Annex VI.

### Claim 74

The method of any of the preceding claims, wherein the preparation or formulation is administered topically.

### Claim 75

The method of any of the preceding claims, wherein the preparation or formulation is administered to the body of the subject, e.g., to one or more of the face, neck, scalp, limb, hand, foot, back, buttock, torso, genitals, and chest of the subject.

### Claim 76

The method of any of the preceding claims, wherein the preparation or formulation is administered intranasally.

### Claim 77

The method of any of the preceding claims, comprising administering the preparation or formulation to the subject orally, enterally, intranasally, parenterally, subcutaneously, ocularly, otically, or respiratorilly.

### Claim 78

The method of any of the preceding claims, wherein the preparation comprises AOM in a buffer solution, e.g., an aqueous buffer solution.

### Claim 79

The method of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, comprises disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 80

The method of any of the preceding claims, wherein the buffer solution e.g., aqueous buffer solution, consisting essentially of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 81

The method of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, consists of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 82

The method of any of the preceding claims, wherein the AOM comprise ammonia oxidizing bacteria (AOB).

### Claim 83

The method of any of the preceding claims, wherein the AOM consist essentially of AOB.

### Claim 84

The method of any of the preceding claims, wherein the AOM consist of AOB.

### Claim 85

The method of any of the preceding claims, wherein the AOM comprise Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio, and combinations thereof.

### Claim 86

The method of any of the preceding claims, wherein the AOM is Nitrosomonas eutropha (N. eutropha).

### Claim 87

The method of any of the preceding claims, wherein the AOM is N. eutropha D23, having ATCC accession number PTA-121157.

### Claim 88

The method of any of the preceding claims, wherein the AOM comprise ammonia oxidizing archaea (AOA).

### Claim 89

The method of any of the preceding claims, wherein administration provides for treatment of one or more of: headaches, cardiovascular diseases, inflammation, immune responses, autoimmune disorders, liver diseases, infections, neurological diseases, psychiatric disorders, pulmonary diseases, nitric oxide disorders, urea cycle disorders, congestion, vasodilation disorders, skin diseases, ophthalmic disorders, bowel disorders, auditory diseases, wound healing, reactions to insect bites, connective tissue disorders, and certain viral, bacterial, or fungal infections.

### Claim 90

The method of any of the preceding claims, wherein administration provides for treatment or improvement of a local effect.

### Claim 91

The method of any of the preceding claims, wherein administration provides for treatment or improvement of a systemic effect.

### Claim 92

The method of any of the preceding claims, comprising:
obtaining the preparation comprising ammonia oxidizing microorganisms (AOM);
preparing a cosmetic, therapeutic, or consumer product from the preparation;
measuring at least one of AOM metabolic activity and Th1, Th2, Th17, or Treg inhibition activity of the AOM in the preparation or product to provide an activity value;
comparing the activity value to a range of pre-determined values corresponding to a pre-determined range of amounts of AOM metabolic activity and Th1, Th2, Th17, or Treg inhibition activity;
determining if the activity value is a value in the range of pre-determined values,
wherein:
if the activity value is in the range of pre-determined values, classifying the preparation or product as accepted; or
if the activity value is outside the range of pre-determined values, classifying the preparation or product as not accepted.

### Claim 93

The method of any of the preceding claims, further comprising heat killing a target percentage of the ammonia oxidizing microorganisms, e.g., if the preparation is not accepted.

### Claim 94

A method of treating a subject, comprising:
administering to the subject a therapeutically effective amount of a preparation comprising ammonia oxidizing microorganisms (AOM),
wherein the preparation was distributed by a method of any of the preceding claims.

### Claim 95

A shelf-stable preparation, comprising:
at least about 103 cells/mL of ammonia oxidizing microorganisms (AOM); and
one or more of the following properties:
less than about 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.5%, or 0.1% of the ammonia oxidizing microorganisms are viable;
the preparation has a viscosity of at least about 1 mPa·s, 10 mPa·s, 100 mPa·s, 1 Pa s, 5 Pa·s, 10 Pa·s, or 20 Pa·s at room temperature, e.g., between about 20° C.-25° C.;
the preparation is formulated as a powder, cream, ointment, salve, or lotion;
the preparation comprises a component that is toxic to AOM, e.g., an antimicrobial or preservative, e.g., a preservative listed in Annex VI; and
the preparation has been sterilized.

### Claim 96

A shelf-stable preparation, comprising:
at least about 103 CFU/mL in 750-1000 mg of ammonia oxidizing microorganisms (AOM); and
at least one preservative listed in Annex VI, wherein the preparation comprises at least 500 ppb of the at least one preservative.

### Claim 97

A shelf-stable preparation, comprising:
at least about 103 CFU/mL in 750-1000 mg of ammonia oxidizing microorganisms (AOM); and
at least one preservative listed in Annex VI,
wherein the preparation if exposed to challenge with a pathogenic microorganism, will not support growth of the pathogenic microorganism.

### Claim 98

The preparation of any of the preceding claims, wherein the preparation comprises at least 500 ppb of the at least one preservative listed in Annex VI.

### Claim 99

The preparation of any of the preceding claims, wherein the preparation comprises a component that is toxic to AOM, e.g., an antimicrobial.

### Claim 100

The preparation of any of the preceding claims, comprising at least about 103 cells/mL, 104 cells/mL, 105 cells/mL, or 106 cells/mL.

### Claim 101

The preparation of any of the preceding claims, comprising at least about 103 CFU/mL, 104 CFU/mL, 105 CFU/mL, or 106 CFU/mL.

### Claim 102

The preparation of any of the preceding claims, wherein the preparation has been sterilized.

### Claim 103

The preparation of any of the preceding claims, wherein the preparation is substantially free of polyphosphate.

### Claim 104

The preparation of any of the preceding claims, wherein, the preparation if exposed to challenge with a population of a pathogenic microorganism, will sterilize at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the population of the microorganism.

### Claim 105

The preparation of any of the preceding claims, wherein the preparation is formulated as a liquid, e.g., spray, aerosol, or mist.

### Claim 106

The preparation of any of the preceding claims, wherein the preparation is formulated as a powder, cream, ointment, salve, or lotion.

### Claim 107

The preparation of any of the preceding claims, wherein the preparation comprises a thickener and/or emulsifier.

### Claim 108

The preparation of any of the preceding claims, wherein the preparation has a viscosity of at least about 1 mPa·s, 10 mPa·s, 100 mPa·s, 1 Pa·s, 5 Pa·s, 10 Pa·s, or 20 Pa·s at room temperature, e.g., between about 20° C.-25° C.

### Claim 109

The preparation of any of the preceding claims, wherein the preparation comprises a talcum powder or cornstarch.

### Claim 110

The preparation of any of the preceding claims, packaged in an end use container.

### Claim 111

The preparation of any of the preceding claims, wherein the end use container indicates one or more of the following:
storage and handling of the preparation;
formulation of the preparation;
description of contents in the preparation;
viability status of the AOM; and
directions for use of the preparation.

### Claim 112

The preparation of any of the preceding claims, wherein the end use container does not indicate one or more of the following:
storage and handling of the preparation;
formulation of the preparation;
description of contents in the preparation;
viability status of the AOM; and
directions for use of the preparation.

### Claim 113

The preparation of any of the preceding claims, wherein the end use container informs the subject to apply the preparation topically.

### Claim 114

The preparation of any of the preceding claims, wherein the end use container informs the subject to apply the preparation intranasally.

### Claim 115

The preparation of any of the preceding claims, wherein the end use container informs the subject to apply the preparation at least one of orally, enterally, intranasally, parenterally, subcutaneously, ocularly, otically, or respiratorilly.

### Claim 116

The preparation of any of the preceding claims, wherein the end use container, comprises a polymer bottle, e.g., a spray, aerosol, or mist bottle.

### Claim 117

The preparation of any of the preceding claims, wherein the end use container, comprises a squeezable container, e.g., squeeze bottle or tube.

### Claim 118

The preparation of any of the preceding claims, wherein the end use container, is substantially free of a vacuum bag.

### Claim 119

The preparation of any of the preceding claims, wherein the end use container, is not configured to inhibit or reduce retrograde flow.

### Claim 120

The preparation of any of the preceding claims, wherein the end use container comprises polymer, e.g., polyethylene terephthalate (PET), high density polyethylene (HDPE), polypropylene, polycarbonate, polytetrafluoroethylene (Teflon®), polyviylidene fluoride (PVDF), or a cellulosic, glass, aluminum, or cardboard.

### Claim 121

The preparation of any of the preceding claims, wherein the end use container, is configured to allow passage of oxygen.

### Claim 122

The preparation of any of the preceding claims, wherein the end use container, is configured to allow passage of at least about 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 99, or 100 percent of transmission of ionizing radiation, e.g., with gamma rays, e.g., with x-rays, e.g., from an isotope, e.g., cobalt 60, or with ultraviolet, e.g., ultraviolet C (UVC) through the container.

### Claim 123

The preparation of any of the preceding claims, wherein the preparation is formulated for oral, enteral (e.g., buccal, sublingual, sublabial, and rectal), parenteral (e.g., subcutaneous, intradermal, intramuscular, intravenous, and intraarticular), inhalation (e.g., fine particle dusts or mists which may be generated by means of various types of metered doses, pressurized aerosols, nebulizers or insufflators, and including intranasally or via the lungs), intranasal, eye, ear, rectal, injection, urogenital, or topical (e.g., dermal, transdermal, transmucosal, buccal, sublingual, and intraocular) administration.

### Claim 124

The preparation of any of the preceding claims, wherein the preparation is formulated for treatment of one or more of: headaches, cardiovascular diseases, inflammation, immune responses, autoimmune disorders, liver diseases, infections, neurological diseases, psychiatric disorders, nitric oxide disorders, urea cycle disorders, congestion, vasodilation disorders, skin diseases, ophthalmic disorders, wound healing, reactions to insect bites, connective tissue disorders, and certain viral, bacterial, or fungal infections.

### Claim 125

The preparation of any of the preceding claims, wherein the preparation is formulated for treatment of a disease or disorder modulated by an activated immune cell.

### Claim 126

The preparation of any of the preceding claims, wherein the activated immune cell is a T helper cell or regulatory T cell, e.g., T helper type 1 (Th1), T helper type 2 (Th2), T helper type 17 (Th17), or regulatory T cell (Treg).

### Claim 127

The preparation of any of the preceding claims, wherein the preparation is formulated for upregulation, activation, downregulation, or suppression of a cytokine associated with an activated immune cell, e.g., IL-5, IL-13, IL-4, IFNγ, IL-12, IL-2, IL-18, IL-17, IL-21, IL-22, IL-10, and TFG-β.

### Claim 128

The preparation of any of the preceding claims, wherein the preparation is formulated for treatment of a Th1 mediated disease or disorder, e.g., Celiac disease, multiple sclerosis, or diabetes, e.g., type 1 diabetes.

### Claim 129

The preparation of any of the preceding claims, wherein the preparation is formulated for treatment of a Th2 mediated disease or disorder, e.g., atopic dermatitis, allergic rhinitis, asthma, or itch.

### Claim 130

The preparation of any of the preceding claims, wherein the preparation is formulated for treatment of a Th17 mediated disease or disorder, e.g., Job's syndrome, rheumatoid arthritis, irritable bowel syndrome.

### Claim 131

The preparation of any of the preceding claims, wherein the preparation is formulated for treatment of a Treg mediated disease or disorder, e.g., immunodysregulation polyendocrinopathy enteropathy-X-linked (IPEX).

### Claim 132

The preparation of any of the preceding claims, wherein the preparation comprises AOM in a buffer solution, e.g., an aqueous buffer solution.

### Claim 133

The preparation of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, comprises disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 134

The preparation of any of the preceding claims, wherein the buffer solution e.g., aqueous buffer solution, consisting essentially of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 135

The preparation of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, consists of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 136

The preparation of any of the preceding claims, wherein the AOM comprise ammonia oxidizing bacteria (AOB).

### Claim 137

The preparation of any of the preceding claims, wherein the AOM consist essentially of AOB.

### Claim 138

The preparation of any of the preceding claims, wherein the AOM consist of AOB.

### Claim 139

The preparation of any of the preceding claims, wherein the AOM comprise Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio, and combinations thereof.

### Claim 140

The preparation of any of the preceding claims, wherein the AOM is Nitrosomonas eutropha (N. eutropha).

### Claim 141

The preparation of any of the preceding claims, wherein the AOM is N. eutropha D23, having ATCC accession number PTA-121157.

### Claim 142

The preparation of any of the preceding claims, wherein less than about 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 1%, 0.5%, or 0.1% of the ammonia oxidizing microorganisms are viable.

### Claim 143

The preparation of any of the preceding claims, wherein at least about 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 99.5%, or 99.9% of the ammonia oxidizing microorganisms are inactive.

### Claim 144

A method of treating a subject, comprising:
administering to the subject a therapeutically effective amount of the preparation of any of the preceding claims,
thereby treating the subject.
